Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
Table 5
Cox model for the effect of bone metastasis combined with another metastatic organ site on OS stratified by study.
Parameter
Levels
Hazard ratio for first-line treatment (95% CI)
value (first line)
Hazard ratio for second-line or higher treatment (95% CI)
value (second line or higher)
Bone and liver metastases
Bone present—liver absent
1.00
0.114
1.00
0.436
Bone present—liver present
1.83 (0.86, 3.90)
1.56 (0.51, 4.79)
Bone and lymph node metastases
Bone present—lymph nodes absent
1.00
0.001
1.00
0.389
Bone present—lymph nodes present
2.97 (1.53, 5.78)
1.59 (0.55, 4.54)
Bone and lung metastases
Bone present—lung absent
1.00
0.881
1.00
0.915
Bone present—lung present
0.93 (0.37, 2.36)
0.92 (0.19, 4.47)
Bone and soft-tissue metastases
Bone present—soft-tissue absent
1.00
0.278
1.00
0.679
Bone present—soft-tissue present
0.65 (0.30, 1.42)
0.83 (0.34, 2.02)
Bone and other metastases
Bone present—other absent
1.00
0.044
1.00
0.497
Bone present—other present
0.45 (0.21, 0.98)
0.68 (0.23, 2.04)
Hazard ratios were adjusted for demographic characteristics, histological entity, tumour grade, site of primary tumour, and time between histological diagnosis and registration/randomisation.
